Accellix Expands its Leadership Team
SAN JOSE, Calif. & JERUSALEM--(BUSINESS WIRE)--#biotechnology--Accellix Inc. is pleased to announce that Terrance Gin is joining its leadership team as Vice President Global Operations effective immediately.
Terrance brings over 30 years of management experience in IVD manufacturing, process and product development, clinical laboratory operations, quality assurance, capital improvement, facility, and EH&S. He was VP of Operations at Singulex in charge of building the operational functions supporting the growth of RUO and clinical testing businesses and Senior Director of Manufacturing at Cepheid responsible for instrument and consumable production. He has recently worked as the Engineering Leader at Becton Dickinson and Thermo Fisher Scientific, improving, and scaling up their production processes and equipment. Over the course of his career, Terrance has worked with flow cytometry, microfluidics, lateral flow, PCR and automated laboratory and manufacturing systems. He holds a BS in Chemistry from UC Berkeley and a MS in Chemical Engineering from San Jose State University.
Nir Nimrodi, Chairman and CEO, said: “Our company is rapidly growing. From supporting 2 customers two years ago, we are now supporting more than 20 leading biopharmaceutical companies in their efforts to develop lifesaving cell therapies. As the number of customers is expected to continue growing, we wish to elevate the quality of everything that we do even further. “
Terrance commented, “Having spent a good portion of my career scaling up operations and launching products in the demanding life science space, I recognize the strong connection between a clear market need and the great solution that Accellix is presenting. I am excited to join Accellix’s strong team in the pursuit of enabling our customers to achieve their goals.”
In addition to the expansion of the leadership team, Accellix added a new role of VP Products. Reed Hickey, who has served as Vice President Operations until now, will assume this new role.
Reed added: “Our future growth will benefit from accelerating the launch of our custom and catalog products. I will operate with the goal of turning the Accellix Platform into the cell therapy gold standard. We are currently developing more than twenty assays that will allow for the migration from traditional flow cytometers to the Accellix Cartridge Based Platform. The faster we can accomplish this effort, the faster our customers will benefit from a streamlined and automated quality control process for their cell therapies. “